Secukinumab: Fully human anti-IL-17 monoclonal antibody Report uri icon

Overview

MeSH Major

  • Breast Implantation
  • Collagen
  • Skin, Artificial
  • Tissue Expansion Devices

abstract

  • Secukinumab (AIN-457) is a fully human monoclonal antibody that neutralizes IL-17, thus affecting the immune response driven by Th17 lymphocytes. The Th17 response has been described to contribute to the inflammatory reaction seen in multiple immune-mediated diseases. Moreover, studies in animal models of autoimmune disease have proven the biological effects of the blockade of IL-17. Mostly, a decrease in the clinical signs and progression of certain immune-mediated diseases was noted. Recently, the results of the use of secukinumab in patients with psoriasis, rheumatoid arthritis, noninfectious uveitis and ankylosing spondylitis have been encouraging. Anti-IL-17 therapy may therefore offer a new therapeutic strategy for patients with immune-mediated diseases. Copyright © 2011 Prous Science, S.A.U. or its licensors. All rights reserved.

publication date

  • January 2011

Research

keywords

  • Report

Identity

Digital Object Identifier (DOI)

  • 10.1358/dof.2011.036.06.1598231

Additional Document Info

start page

  • 441

end page

  • 445

volume

  • 36

number

  • 6